By Colin Kellaher

 

AbbVie Inc. on Monday said it has filed with the U.S. Food and Drug Administration and the European Medicines Agency for expanded approval of Rinvoq for the treatment of adults and adolescents with moderate to severe atopic dermatitis, a chronic, inflammatory skin disease more widely known as eczema.

The North Chicago, Ill., biopharmaceutical company said the applications are supported by data from three pivotal phase 3 studies in which Rinvoq showed significant improvement in skin clearance and reduction in itch compared with placebo.

AbbVie last year received U.S. and European approval for Rinvoq for adults with moderately to severely active rheumatoid arthritis. The company in August filed for U.S. and European approval for the drug in adults with active ankylosing spondylitis.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 19, 2020 10:38 ET (14:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more AbbVie Charts.